MSK
Search
- Page Path
- HOME > Search
Review
- Middle East Respiratory Syndrome coronavirus vaccine development: updating clinical studies using platform technologies
- Jung-ah Choi , Jae-Ouk Kim
- J. Microbiol. 2022;60(3):238-246. Published online January 28, 2022
- DOI: https://doi.org/10.1007/s12275-022-1547-8
- 75 View
- 0 Download
- 10 Web of Science
- 6 Crossref
-
Abstract
- Middle East Respiratory Syndrome coronavirus (MERS-CoV), a contagious zoonotic virus, causes severe respiratory infection with a case fatality rate of approximately 35% in humans. Intermittent sporadic cases in communities and healthcare facility outbreaks have continued to occur since its first identification in 2012. The World Health Organization has declared MERS-CoV a priority pathogen for worldwide research and vaccine development due to its epidemic potential and the insufficient countermeasures available. The Coalition for Epidemic Preparedness Innovations is supporting vaccine development against emerging diseases, including MERS-CoV, based on platform technologies using DNA, mRNA, viral vector, and protein subunit vaccines. In this paper, we review the usefulness and structure of a spike glycoprotein as a MERSCoV vaccine candidate molecule, and provide an update on the status of MERS-CoV vaccine development. Vaccine candidates based on both DNA and viral vectors coding MERSCoV spike gene have completed early phase clinical trials. A harmonized approach is required to assess the immunogenicity of various candidate vaccine platforms. Platform technologies accelerated COVID-19 vaccine development and can also be applied to developing vaccines against other emerging viral diseases.
-
Citations
Citations to this article as recorded by
- Structure-Guided Design of Potent Coronavirus Inhibitors with a 2-Pyrrolidone Scaffold: Biochemical, Crystallographic, and Virological Studies
Chamandi S. Dampalla, Yunjeong Kim, Alexandria Zabiegala, Dennis J. Howard, Harry Nhat Nguyen, Trent K. Madden, Hayden A. Thurman, Anne Cooper, Lijun Liu, Kevin P. Battaile, Scott Lovell, Kyeong-Ok Chang, William C. Groutas
Journal of Medicinal Chemistry.2024; 67(14): 11937. CrossRef - Role of vaccination in patients with human monkeypox virus and its cardiovascular manifestations
Khawaja Usama Maqbool, Muhammad Talha Akhtar, Shayan Ayub, FNU Simran, Jahanzeb Malik, Maria Malik, Rafia Zubair, Amin Mehmoodi
Annals of Medicine & Surgery.2024; 86(3): 1506. CrossRef - The many facets of CD26/dipeptidyl peptidase 4 and its inhibitors in disorders of the CNS – a critical overview
Hans-Gert Bernstein, Gerburg Keilhoff, Henrik Dobrowolny, Johann Steiner
Reviews in the Neurosciences.2023; 34(1): 1. CrossRef - MERS-CoV recently re-emerged in Qatar, Saudi Arabia, its feasible global health risks amid FIFA world cup 2022 and salient counteracting strategies – an update
Hitesh Chopra, Md. Aminul Islam, Deepak Chandran, Talha B. Emran, Nahed A. El-Shall, Jaffar A. Al-Tawfiq, Kuldeep Dhama
International Journal of Surgery.2023; 109(2): 153. CrossRef - Two years of COVID-19 pandemic: where are we now?
Jinjong Myoung
Journal of Microbiology.2022; 60(3): 235. CrossRef - Comparing the Immunogenicity and Protective Effects of Three MERS-CoV Inactivation Methods in Mice
Nayoung Kim, Tae-Young Lee, Hansaem Lee, Jeong-Sun Yang, Kyung-Chang Kim, Joo-Yeon Lee, Hyun-Joo Kim
Vaccines.2022; 10(11): 1843. CrossRef
- Structure-Guided Design of Potent Coronavirus Inhibitors with a 2-Pyrrolidone Scaffold: Biochemical, Crystallographic, and Virological Studies
First
Prev
TOP
